

# Is the prevalence of arterial hypertension in rheumatoid arthritis and osteoarthritis associated with disease?

---

Morović-Vergles, Jadranka; Šalamon, Lea; Marasović-Krstulović, Daniela; Kehler, Tatjana; Šakić, Davorin; Badovinac, Olga; Vlak, Tonko; Novak, Srđan; Štiglić-Rogoznica, Nives; Hanih, Marino; ...

Source / Izvornik: **Rheumatology International**, 2013, 33, 1185 - 1192

Journal article, Accepted version

Rad u časopisu, Završna verzija rukopisa prihvaćena za objavljivanje (postprint)

<https://doi.org/10.1007/s00296-012-2522-1>

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:105:367301>

Rights / Prava: [In copyright](#)/[Zaštićeno autorskim pravom](#).

Download date / Datum preuzimanja: **2025-03-10**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine Digital Repository](#)





## Središnja medicinska knjižnica

**Morović-Vergles J., Šalamon L., Marasović-Krstulović D., Kehler T., Šakić D., Badovinac O., Vlak T., Novak S., Štiglić-Rogoznica N., Hanih M., Bedeković D., Grazio S., Kadojić M., Milas-Ahić J., Prus V., Stamenković D., Šošo D., Anić B., Babić-Naglić Đ., Gamulin S. (2013) *Is the prevalence of arterial hypertension in rheumatoid arthritis and osteoarthritis associated with disease?* *Rheumatology International*, 33 (5). pp. 1185-92. ISSN 0172-8172**

<http://www.springer.com/journal/296>

<http://link.springer.com/journal/296>

<http://dx.doi.org/10.1007/s00296-012-2522-1>

<http://medlib.mef.hr/2047>

University of Zagreb Medical School Repository

<http://medlib.mef.hr/>

Is the prevalence of arterial hypertension in rheumatoid arthritis and osteoarthritis associated with disease?

Jadranka Morović-Vergles<sup>1</sup>, Lea Šalamon<sup>1</sup>, Daniela Marasović-Krstulović<sup>2</sup>, Tatjana Kehler<sup>3</sup>, Davorin Šakić<sup>4</sup>, Olga Badovinac<sup>4</sup>, Tonko Vlasković<sup>5</sup>, Srđan Novak<sup>6</sup>, Nives Štiglić-Rogoznica<sup>7</sup>, Marino Hanih<sup>8</sup>, Dražen Bedeković<sup>9</sup>, Simeon Grazio<sup>10</sup>, Mira Kadojić<sup>11</sup>, Jasminka Milas-Ahić<sup>9</sup>, Višnja Prus<sup>9</sup>, Doris Stamenković<sup>7</sup>, Daniela Šošo<sup>5</sup>, Branimir Anić<sup>12</sup>, Đurđica Babić-Naglić<sup>13</sup>, Stjepan Gamulin<sup>14</sup>.

<sup>1</sup>Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Dubrava University Hospital, University of Zagreb School of Medicine, Zagreb, Croatia (coordinative center of the study), <sup>2</sup>Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Split University Hospital, University of Split School of Medicine, Split, Croatia, <sup>3</sup>Hospital for Cardiac, Pulmonary and Rheumatic Rehabilitation, Talassotherapia, Opatija, Croatia, <sup>4</sup>Department of Physical Medicine, Dubrava University Hospital, Zagreb, Croatia, <sup>5</sup>Department of Rehabilitation Medicine and Rheumatology, Split University Hospital, University of Split School of Medicine, Split, Croatia, <sup>6</sup>Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Clinical Hospital Center Rijeka, University of Rijeka School of Medicine, Rijeka, Croatia, <sup>7</sup>Department for Rheumatology and Rehabilitation, Clinical Hospital Centre Rijeka, School of Medicine University of Rijeka, Rijeka, Croatia, <sup>8</sup>Department of Rheumatic Diseases, Physical Medicine and Rehabilitation, GH "Dr. Josip Benčević", Slavonski Brod, <sup>9</sup>Department of Internal Medicine, Osijek University Hospital, Osijek, Croatia, <sup>10</sup>Department of Rheumatology, Physical and Rehabilitation Medicine, "Sisters of Charity" Clinical Hospital Center, Referral Center for Spondyloarthropathies, Ministry of Health and Social Welfare, Republic of Croatia, Zagreb, Croatia, <sup>11</sup>Department of Physical Medicine and Rehabilitation, Osijek University Hospital, Osijek, Croatia, <sup>12</sup>Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Zagreb Clinical Hospital Center, University of Zagreb School of Medicine, Zagreb, Croatia, <sup>13</sup>Department of Rheumatology and Rehabilitation, Zagreb Clinical Hospital Center, University of Zagreb School of Medicine, Zagreb, Croatia, <sup>14</sup>Department of Pathophysiology, University of Zagreb School of Medicine, Zagreb, Croatia

Corresponding author:

Prof. Jadranka Morović-Vergles, M.D., Ph.D.

Division of Clinical Immunology and Rheumatology,

Department of Internal Medicine,  
Dubrava University Hospital,  
Av. G. Šuška 6,  
10 040 Zagreb, Croatia  
E-mail: jmorovic@kbd.hr

Short title:

Hypertension in RA and OA

**Abstract**

**Objective.** In this study, we compare the prevalence of HT in RA and OA patients, exposed to high- and low-grade chronic inflammation, respectively , to assess the possible association between chronic inflammation and HT.

**Methods.** A total of consecutive 627 RA and 352 OA patients were enrolled in this multicentric study. HT was defined as a systolic blood pressure (BP)  $\geq 140$  and/or diastolic BP  $\geq 90$  mmHg or current use of any antihypertensive drug. Overweight/obesity was defined as body mass index (BMI)  $\geq 25$ , and patients  $\geq 65$  years old were considered elderly.

**Results.** The prevalence of HT was higher in the OA group than in the RA group [73.3% (95%CI 68.4, 77.7) and 59.5% (95%CI 55.6, 68.4)  $P < 0.001$  respectively]. When the results were adjusted for age and BMI the HT prevalence was similar in both groups [RA 59%(95%CI 55.1, 63.8) OA 60%(95%CI 58.4, 65.0)]. In both groups, the prevalence of HT was higher in the elderly and those who were overweight than in the younger patients and those with a BMI  $< 25$  . Overweight (BMI  $\geq 25$ ) and age  $\geq 65$  were independent predictors of HT in multivariate logistic regression model, which show no association of HT and the disease (RA or OA).

**Conclusion.** The results indicated a robust association of age and BMI with HT prevalence in both RA and OA. The difference in HT prevalence between RA and OA is rather due to age and BMI then to features of the disease, putting into question specific association of HT with RA.

**Key words:** Rheumatoid arthritis, Osteoarthritis, Hypertension

## **Introduction**

Excessive cardiovascular (CV) morbidity and mortality leading to premature death is common in rheumatoid arthritis (RA) patients. The mechanism of this co-morbidity is not well understood. Chronic systemic inflammation is thought to have a pivotal role in increased CV disease risk in RA, contributing to vascular damage (endothelial dysfunction, accelerated atherosclerosis, and atherosclerotic plaque instability) [1].

Among the classic CV risk factors, hypertension (HT) has a prominent role in RA patients [1,2]. An increased prevalence of HT in RA patients was found in a number of studies, but not in all. A 52-73% prevalence of HT in RA patients was found in the studies with a large number of patients that used the current definition of hypertension [3]. The mechanisms leading to frequent HT in RA patients are not clear; the association is likely due to a complex interplay of various factors, including chronic systemic inflammation [3].

CV co-morbidities, particularly HT, have not been investigated in osteoarthritis (OA) patients as extensively as in RA patients. The prevalence of CV disease in OA was found to be approximately 55% [4,5]. The reported prevalence of HT in OA was 40% in one study [6] and 75% in another [7]. The studies comparing CV disease risk in RA and OA are rather scarce. The CV disease risk and the presence of CV disease risk factors in OA were found to be lower [8] or similar [9] to those in RA. The CV disease risk in OA has been attributed to a high prevalence of classic CV disease risk [9], and in the case of HT, to medication, especially the use of non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 inhibitors [10].

The aim of this study is a comparison of HT prevalence and disease features in RA and OA patients. A comparison of the two diseases, which are both characterized by a chronic course and painful joint involvement, but with either high (RA) or low (OA) levels of chronic systemic inflammation [11,12], may reveal an association between various disease features and HT in conditions that differ in terms of the level of chronic systemic inflammation.

## **Patients and methods**

In order to collect data concerning HT prevalence in RA and OA of from all part of the country we preformed this multicentric cross-sectional study in collaboration with outpatient rheumatology clinics in regional medical centers of Croatia (Table 1). A total of 625 RA and 352 OA patients who attended the outpatient clinics from 1 September to 31 December 2009 were consecutively enrolled in the study. The diagnoses of RA and OA (knee, hip and hand) were established by qualified rheumatologists according to the 1987 American College of Rheumatology

(ACR) classification criteria for RA [13] and the ACR criteria for OA [14,15,16]. The study protocol was approved by the Ethical Committee of the Dubrava University Hospital, Zagreb, the coordinative center of the study, and a written informed consent (according to the Declaration of Helsinki) was obtained from all study participants.

All participants underwent a detailed evaluation guided by a questionnaire administered in all collaborative departments. The evaluation included a detailed medical history, physical examination and the measurement of body height and weight. Patients with ischemic heart disease were not included in the study.

In order to compare this study with the study [17] the subgroups comprised all 50-70 yrs old RA and OA patients were selected.

Patients  $\geq 65$  years of age were considered elderly. Body mass index (BMI) was calculated according to the standard formula [18], and patients with BMIs  $\geq 25$  were qualified as overweight (including obesity). Waist and hip circumferences were measured, and the waist-to-hip ratio (WHR) was calculated [19].

Pain and the patients' general health (GH) were assessed using the appropriate visual analog scales (VAS). Pain VAS (VASP) ranged from 0–10, with 10 being the most intensive pain [20]. General health VAS (VASGH) was part of the DAS28-CRP score [21]. VAS was represented by a 100 mm long line on which the patients evaluated their own health, with 100 mm representing the best health. RA patient functional status and disease activity were assessed by the Croatian translation of the Health Assessment Questionnaire (HAQ)[22] and by the DAS28-CRP [20] using a DAS calculator [23], respectively.

All antihypertensive and antirheumatic medications taken by the enrolled patients were recorded in detail (indications, dose and duration of treatment).

Blood pressure (BP) was measured after a 5 min rest in a sitting position on the right arm with a mercury sphygmomanometer and a standard cuff. The recorded BP value for each patient was the mean of three subsequent measurements at 5 min intervals. HA was defined according to the European Society of Hypertension and the European Society of Cardiology 2007 guidelines with BP  $\geq 140$  mmHg and/or diastolic BP  $\geq 90$  mmHg [18] or any BP with antihypertensive treatment. Newly discovered HT was defined as actual HT without HT history and was expressed as the prevalence and the fraction of actual HT. Uncontrolled HT was defined as HT on hypertensive therapy having BP with HT values.

Venous blood samples were collected for laboratory investigations after overnight fasting. The following tests were performed in the laboratories of the collaborative hospitals: erythrocyte

sedimentation rate (ESR), C-reactive protein (CRP), total cholesterol (Chol), high-density lipoproteins (HDL), low-density lipoproteins (LDL), triglycerides (TG), creatinine and plasma glucose (Glc). When required, oral glucose tolerant tests (OGTT) were performed. Diabetes (DM) was defined by a history of DM with current use of antidiabetic medication or fasting Glc  $\geq 7$  mmol/L or Glc in OGTT (2 h)  $\geq 11.1$  mmol/L [24]. The same standard methods were used in all laboratories, and biochemical assays were performed using Olympus autoanalyzers according to the manufacturer's protocol.

#### *Statistical analysis*

The normality of the data distribution was assessed using the Kolmogorov-Smirnov test. Values are presented as median [interquartile range(IQR)], mean (S.D.) or percentage values as appropriate. Comparisons were performed with the Student's t-test, Mann-Whitney U-test and chi-squared test for normally, non-normally distributed and categorical variables, respectively. Binary logistic regression was used to assess the independency of the association of various variables with the prevalence of HT in RA, OA and all patients. P-values  $< 0.05$  (two-tailed) were considered significant. All statistical analyses were performed using SPSS 17.0 software (SPSS Inc., Chicago, USA). The adjustment of HT prevalence for age and BMI was made according to [25].

## **Results**

### *Characteristics of RA and OA patients (Table 2).*

The proportion of female patients was higher than that of men in both the RA and OA groups. In comparison with OA, RA was characterized by younger age, a lower proportion of elderly patients, a longer duration of the disease, a higher proportion of smokers (ever and current), lower BMI and WHR, a lower proportion of overweight/obese patients, similar VASP and VASGH, and lower proportions of dyslipidemic and DM patients.

Laboratory investigations showed higher plasma CRP concentrations and ESR, and lower Chol, TC and Glc plasma concentrations in the RA group. HDL, LDL and plasma creatinine concentrations were similar in both groups of patients.

### *Prevalence of HT in RA and OA patients (Table 3)*

The prevalence of HT was lower in the RA group than in the OA group. However when the results were adjusted for age and BMI the prevalence was similar in both groups. Also HT prevalence in RA and OA of 55-70 yrs subgroups was similar.

The proportion of patients with a history of HT was lower the RA group than in the OA group. The prevalence of newly discovered HT was similar in RA and OA, but newly discovered



HT comprised a higher fraction of actual HT in RA than in OA patients. The rate of uncontrolled HT, expressed as fraction of treated HT was similar in the RA and OA groups.

In both RA and OA, the prevalence of HT was higher in the elderly and overweight/obese patients than in patients under 65 years of age or with BMI values <25. When RA and OA patients less than 65 years of age were sorted according to both age and BMI, the prevalence of HT was higher in overweight/obese patients than in those with BMI values <25. In the elderly, this difference was smaller and statistically insignificant.

Taking cut-off for CRP concentration of 5 mg/L, the prevalence of HT was higher in the RA group with higher CRP concentration than with lower. In the OA there was no such difference.

In both RA and OA patients, the prevalence of HT was higher in DM than in nondiabetic patients. Upon comparing RA and OA, the prevalence of HT in DM was similar in both groups and that in nondiabetics was higher in the latter group than in the former group.

Regarding smoking habit, HT prevalence was higher in non-smoker and ex-smokers than in current smokers in both groups.

The HT prevalence was similar in non-steroidal anti-inflammatory drugs (NSAIDs) users and non-users in both the RA and OA groups. In RA group there was no difference in HT prevalence between glucocorticoid users and non-users, but in current users the prevalence of HT was higher in patients taking glucocorticoids more than less of 3 months.

Results regarding comparison of HT and NT (normotensive) subgroups of RA and OA patients and comparison of hypertensive RA and OA patients are shown in table 1-S and 2-S. (see supplementary data available at *Rheumatology* online)

#### *Multivariate analysis*

Variables that were significantly different comparing the HT and NT subgroups in RA and OA groups were introduced in logistic regression the models. The variables that were independently associated with HT presence in RA and OA were age and BMI (see see supplementary data available at *Rheumatology* online table 2-S). To analyze mutual contribution of these variables to HT prevalence in all patents in a logistic regression model age and BMI as numerical variables and the disease (RA or OA) as categorical variable were introduced (table 4). The analysis indicated independent association of age and BMI with HT prevalence without contribution of features of the disease (RA or OA). From the date generated by the model adjusted HT prevalence were calculated (table 3).

### *Discussion*

The characteristics of our RA and OA patients and their differences are consistent with reported epidemiological and clinical features of the diseases [26], including a higher prevalence in females than in males in both RA and OA; higher age in OA and a longer duration of the disease for RA, higher proportion of smokers in RA, reflect a greater increase in OA prevalence with age and a lower age of onset of RA; and a strong association of BMI with OA and an association of RA with smoking.

The prevalence of HT is associated with age [27] and BMI [28], which explains the higher prevalence of HT in OA. When the results were adjusted for age and BMI the HT prevalence in RA and OA was similar.

In comparison with others studies, the prevalence of HT in RA group was lower than that reported in a similar study of Panoulas et al. [17], The patients in that study was older then in this study [63.1( 55-69.6) v 59.00(52.00-68.00) median (IQR) respectively]. Similar HT prevalence in 55-70 yrs RA subgroups and that in [17] study indicate that the differences in HT prevalence between this study and study [17] is due to difference in age of the patients. Regarding OA, our finding is similar to that reported in one of the previous studies [7].

The overall prevalence of HT in Croatia (44.2%) is similar to that in other European countries [29]. When age was taken into account, only the higher prevalence of HT in OA patients under 65 years old, compared with the prevalence in the general Croatian population, could be assumed (Fig. 1). However, this visual comparison of prevalence and the confidence intervals is rather insufficient, and investigations with proper control groups are needed.

Upon comparing the rates of newly discovered, treated with antihypertensive therapy and uncontrolled HT in our study with rates in the general Croatian population [29] and rates described for RA [28], there was a lower rate for newly discovered HT (reference 29: 44.5%; reference 28: 39.4% vs. this study: 29.9% and 18.6% for RA and OA, respectively), a higher rate for treated HT (reference 29: 44.5%; reference 28: 60.6% vs. this study: 75.1% and 86.0% for RA and OA, respectively) and a lower rate for uncontrolled HT (reference 29: 85.6%; reference 28: 78.36% vs. this study: 41.0% and 50.8% for RA and OA, respectively). This improvement in HT screening and therapy in rheumatologic diseases is probably result of recently increased awareness of HT prevalence in RA [17,30]

In both RA and OA, the association of HT with various variables followed that of HT in general (increased HT prevalence with age and BMI, association of HT with DM and with metabolic variables associated with HT, (see supplementary data available at *Rheumatology* online table 1-S)[18] and were similar to those described for RA [17].

Due to the change in body composition (loss of lean body mass with an increase in fat body mass) in RA, BMI is lower for a given fat mass [31], which should be taken in account when BMI in RA is compared with that in other conditions. Alternatively, we measured WHR, which correlates with visceral adipose tissue and CV disease risk [19]. The higher WHR in OA (all patients) indicates a higher visceral adiposity in OA than in RA. Lower BMI values and similar WHRs in HT RA versus HT OA patients may indicate an underestimation of overweight and obesity in the former group (see Supplementary data table 1-S).

The prevalence of HT in subgroups defined by both age and BMI (higher in the subgroup with  $BMI \geq 25$  than  $BMI < 25$  in patients  $< 65$  years of age and similar regarding BMI in patients  $\geq 65$  years of age) indicated a stronger association between age and HT than between BMI and HT.

Smoking has been shown to be a risk factor for HT in general [18], and an association with HT in RA has been described [17]. The lack of association of smoking with HT in both RA and OA in our study might be explained by the higher age of nonsmokers versus current smokers and ex-smokers in both the RA and OA groups (results not shown).

Higher values for markers of inflammation (ESR, CRP concentration) in RA compared to OA, as well as in the RA HT subgroup compared to NT RA (see supplementary data available at *Rheumatology* online 1-S) and higher HT prevalence in  $CRP > 5\text{mg/L}$  than in  $CRP < 5\text{mg/L}$  RA subgroup, show a higher grade of systemic inflammation in RA than in OA and an association of HT with degree of systemic inflammation in RA, respectively. This association was rather weak because it was not expressed in the multivariate analysis (see supplementary data available at *Rheumatology* online table 2-S), and there was no association of disease activity and HT assessed by the DAS28-CRP (see supplementary data available at *Rheumatology* online table 1). In a retrospective study, an association between CRP concentration and HT was shown in RA [2], whereas no association of HT with either CRP or DAS was found in the cross-sectional study [17]. A causative role of systemic inflammation in the pathogenesis of HT in RA was proposed, but there was no conclusive evidence for that hypothesis [3,17]. Cross-sectional studies with one point of measurement for inflammatory markers and HT, such as this study and that reported in [17], are not adequate to answer questions regarding the duration of disease, and future longitudinal studies are essential.

Antirheumatic therapy may provoke HT or interfere with its control, particularly in the case of NSAIDs used for the treatment of OA [10] and RA and for various DMARDs and GCs used to treat RA [3]. Our results, which showed no association of HT with NSAID use in RA and OA and an association of HT with leflunomide use (see supplementary data available at *Rheumatology*

online, table 1-S) and with the duration of GC use in RA were similar to the findings of others for RA [17,32].

Finally, age and BMI were the only variables that were independently associated with HT in both the RA and OA groups and with difference in HT presence between RA and OA. However, age and BMI, which are higher in OA than in RA, act as confounding variables that may obscure the association of other variables with HT, particularly systemic inflammation [33], and the influence of these variables could not be excluded.

Confounding effect of age and BMI has to be taken in account in comparison of HT prevalence between RA and OA and with other conditions to avoid erroneously conclusions.

In conclusion, this cross-sectional study has shown a robust association of age and BMI with HT prevalence in both RA and OA. The difference in HT prevalence between RA and OA is rather due to age and BMI than due to features of the disease, putting into question specific association of HT and RA [3].

Indirect comparison showed that HT prevalence in RA in our study was similar to the Croatian general population. For OA, HT prevalence was higher than that of the Croatian general population under 65 years old and similar to that over 65 years old.

#### **Key message**

The difference in HT prevalence between RA and OA is due to age and BMI.

Confounding effect of age and BMI could lead to erroneously conclusions on HT prevalence.

HT prevalence in RA is similar to that in general population in Croatia.

#### **Acknowledgements**

The authors thank Professor Davor Eterovic, Ph.D. of the University of Split Medical School for statistical advice.

#### **Funding**

This work was supported by a grant from the Ministry of Science, Education and Sport, the Republic of Croatia (198-1081874-0183 to JMV).

#### **Disclosure statement**

The authors declare no conflicts of interest.

### **References**

#### **References**

1. John H, Kitas G, Toms T, Goodson N. Cardiovascular co-morbidity in early rheumatoid

- arthritis. *Best Pract Res Clin Rheumatol* 2009;23:71-82.
2. Serelis J, Panagiotakos DB, Mavrommati M, Skopouli FN. Cardiovascular disease is related to hypertension in patients with rheumatoid arthritis: a greek cohort study. *J Rheumatol* 2011;38:236-41.
  3. Panoulas VF, Metsios GS, Pace AV, et al. Hypertension in rheumatoid arthritis. *Rheumatology (Oxford)* 2008;47:1286-98.
  4. Marks R, Allegrante JP. Comorbid disease profiles of adults with end-stage hip osteoarthritis. *Med Sci Monit* 2002;8:CR305-9.
  5. van Dijk GM, Veenhof C, Schellevis F, et al. Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee. *BMC Musculoskelet Disord* 2008;9:95.
  6. Singh G, Miller JD, Lee FH, Pettitt D, Russell MW. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey. *Am J Manag Care* 2002;8(15 Suppl):S383-91
  7. Gabriel SE, Crowson CS, O'Fallon WM. Comorbidity in arthritis. *J Rheumatol* 1999;26:2475-9.
  9. Erb N, Pace AV, Douglas KMJ, Banks MJ, Kitas GD. Risk assessment for coronary heart disease in rheumatoid arthritis and osteoarthritis. *Scand J Rheumatol* 2004;33:293-9.
  10. Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. Emerging therapeutic strategies in osteoarthritic patients with hypertension. In *Optimising the management of osteoarthritis:emerging therapies*, London BMJ Group 2010:8-12
  11. Sipe JD. Acute-phase proteins in osteoarthritis. *Semin Arthritis Rheum* 1995;25:75-86
  12. Morovic-Vergles J, Culo MI, Gamulin S, Culo F. Cyclic adenosine 5'-monophosphate in synovial fluid of rheumatoid arthritis and osteoarthritis patients. *Rheumatol Int*. 2008;29:167-71.
  13. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24.
  14. Altman R, Alarcon G, Appelrouth D, Bloch D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. *Arthritis Rheum* 1991;34:505-14.
  15. Altman R, Alarcon G, Appelrouth D, Bloch D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. *Arthritis Rheum* 1990;33:1601-10.

16. Altman R, Asch E, Bloch D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the knee. *Arthritis Rheum* 1986;29:1039-49.
17. Panoulas VF, Douglas KMJ, Milionis HJ, Stavropoulos-Kalinglou A, Nightingale P, Kita MD, et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. *Rheumatol* 2007;46:1477-82.
18. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J* 2007;28:1462-536.
19. See R, Abdullah SM, McGuire DK, et al. The association of differing measures of overweight and obesity with prevalent atherosclerosis: the Dallas Heart Study. *J Am Coll Cardiol* 2007;50:752-9.
20. Mannion AF, Balagué F, Pellisé F, Cedraschi C. Pain measurement in patients with low back pain. *Nat Clin Pract Rheumatol* 2007;3:610-8.
21. DAS-score. nl: Disease activity score in rheumatic arthritis: <http://www.das-score.nl/> (21 March 2011, date last accessed)
22. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. *Br J Rheumatol* 1986;25:206-209.
23. The DAS calculator: <http://www.das-score.nl/dascalators.html> (21 March 2011, date last accessed).
24. World Health Organization. Dept. of Noncommunicable Disease Surveillance. Definition and diagnostic criteria for diabetes mellitus and other categories of glucose intolerance. In: Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. Geneva, World Health Organization, 1999:2-8.
25. Zhang J, Yu KF. What's the relative risk? *JAMA* 1998;280:1690-1.
26. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. *Bull World Health Organ* 2003;81:646-56.
27. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension Prevalence and Blood Pressure Levels in 6 European Countries, Canada, and the United States. *JAMA*: 2003;289:2363-9.
28. Aneja A, El-Atat F, McFarlane SI, Sowers JR. Hypertension and Obesity. *Recent Prog Horm Res* 2004;59:169-205.

29. Erceg M, Hrabak-Zerjavić V, Ivcević Uhernik A. Regional characteristics of arterial hypertension in adult population of Croatia. *Acta Med Croatica* 2007;61:293-8. (Croatian).
30. Dessein PH, Norton GR. Should patients with RA be aggressively monitored for hypertension? *Nat Clin Pract Rheumatol* 2008;4:18-9.
31. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, et al. Redefining overweight and obesity in rheumatoid arthritis patients. *Ann Rheum Dis* 2007;66:1316-21.
32. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. *Rheumatology* 2008;47:72–5.
33. Fernández-Real JM, Ricart W (2003) Insulin resistance and chronic cardiovascular inflammatory syndrome. *Endocr Rev* 24:278-301

Online Resource

**Is the prevalence of arterial hypertension in rheumatoid arthritis and osteoarthritis associated with disease?**

**Rheumatology International**



Table 1-S. Hypertensive and normotensive patients in RA<sup>a</sup> and OA<sup>b</sup>

|  | RA (N=627)                 |                            |                     | P value (HTRA vs. HTOA) | OA (N=352)                 |                           |                     |
|--|----------------------------|----------------------------|---------------------|-------------------------|----------------------------|---------------------------|---------------------|
|  | HT <sup>c</sup> (N=373)    | NT <sup>d</sup> (N=254)    | P-value( HT vs. NT) |                         | HT (N=258)                 | NT (N=94)                 | P-value (HT vs. NT) |
| Sex female, n[% (95%CI <sup>e</sup> )] | 314<br>[84.2 (80.2, 87.6)] | 208<br>[81.0 (75.7, 85.3)] | 0.450               | 0.435                   | 223<br>[86.4 (81.7, 90.0)] | 72<br>[76.6 (67.1, 84.0)] | 0.027               |
| Age, yrs                               | 63.0 (56.0-70.0)           | 54.0 (45.0-62.0)           | <0.001              | <0.001                  | 69.0 (61.0-74.0)           | 59.0 (50.0-69.0)          | <0.001              |
| Aged ≥65 yrs, n[% (95%CI)]             | 157<br>[42.1 (37.2, 47.2)] | 51<br>[20.1 (15.6, 25.5)]  | <0.001              | <0.001                  | 167<br>[64.7 (58.7, 70.3)] | 32<br>[34.0 (25.2, 44.0)] | <0.001              |
| Disease duration (yrs)                 | 8.0 (3.0 -16.0)            | 5.0 (2.0 -12.0)            | 0.002               | 0.008                   | 6.00 (2.0-12.0)            | 3.0 (1.0-7.0)             | <0.001              |
| HT awareness (yrs)                     | 7.0 (3.0-13.0)             | 0                          | ND <sup>g</sup>     | 0.002                   | 9.0 (5.0-16.0)             | 0                         | ND                  |
| BMI <sup>f</sup>                       | 27.17<br>(24.66 - 30.26)   | 25.30<br>(22.58 -28.03)    | <0.001              | <0.001                  | 30.41<br>(26.73 -33.00)    | 27.50<br>(24.96 - 31.03)  | <0.001              |
| BMI ≥ 25 n[% (95%CI)]                  | 266<br>[71.3 (66.5, 75.7)] | 129<br>[50.7 (44.6, 56.8)] | <0.001              | <0.001                  | 218<br>[85.2 (80.4, 89.0)] | 70<br>[74.5 (64.8, 82.2)] | 0.020               |
| W/H <sup>h</sup> ratio                 | 0.90<br>(0.85 - 0.95)      | 0.86<br>(0.80 - 0.92)      | <0.001              | 0.464                   | 0.90<br>(0.85 - 0.96)      | 0.89<br>(0.82 - 0.96)     | 0.177               |
| VASP <sup>i</sup>                      | 50.00<br>(39.00 - 70.00)   | 50.00 (25.25 - 70.00)      | 0.007               | 0.340                   | 55.00<br>(40.00 - 70.00)   | 40.00<br>(28.00 - 50.00)  | <0.001              |
| VASGH <sup>j</sup>                     | 50.00<br>(30.00 - 70.00)   | 42.00<br>(20.00 - 60.00)   | 0.064               | 0.618                   | 50.00<br>(30.00 - 64.50)   | 43.50<br>(30.00 - 60.00)  | 0.147               |
| HAQ <sup>k</sup>                       | 1.50<br>(0.70 - 2.13)      | 1.19<br>(0.60 - 1.88)      | 0.002               |                         | ND                         | ND                        | ND                  |
| DAS28-CRP <sup>l</sup>                 | 4.41 (1.52)                | 4.21 (1.58)                | 0.129               |                         | ND                         | ND                        |                     |
| Dyslipidemia, n[% (95%CI)]             | 173<br>[46.4 (41.4, 51.5)] | 76<br>[29.9 (24.6, 35.8)]  | <0.001              | 0.030                   | 147<br>[57.0 (50.9, 62.9)] | 37<br>[39.4 (30.1, 49.5)] | 0.010               |
| DM <sup>m</sup> n[% (95%CI)]           | 47<br>[12.6 (9.6, 16.4)]   | 13<br>[5.1 (3.0, 8.5)]     | 0.002               | 0.010                   | 52<br>[20.2 (15.8, 25.5)]  | 7<br>[7.4 (3.6, 14.5)]    | 0.005               |
| <i>Laboratory data</i>                 |                            |                            |                     |                         |                            |                           |                     |
| ESR <sup>n</sup>                       | 28 (15 – 45)               | 22 (12 – 40)               | 0.007               | <0.001                  | 15 (9- 24)                 | 12 (8 – 20)               | 0.114               |
| CRP <sup>o</sup> (mg/L)                | 9.40<br>(4.00-21.00)       | 6.70<br>(2.38-16.94)       | 0.007               | <0.001                  | 2.95<br>(1.30-3.83)        | 2.00<br>(1.40 – 3.10)     | 0.016               |
| Chol <sup>p</sup> (mmol/L)             | 5.61<br>(4.90 – 6.50)      | 5.30<br>(4.73 – 5.90)      | <0.001              | 0.565                   | 5.80<br>(4.84 – 6.60)      | 5.70<br>(4.80 – 6.38)     | 0.263               |
| TG <sup>q</sup> (mmol/L)               | 1.45<br>(1.10 – 1.90)      | 1.22<br>(0.93 – 1.60)      | <0.001              | <0.001                  | 1.700<br>(1.30 – 2.31)     | 1.60<br>(1.09 – 1.90)     | 0.008               |

|  |                            |                            |        |        |                            |                            |       |
|--|----------------------------|----------------------------|--------|--------|----------------------------|----------------------------|-------|
| HDL <sup>r</sup> (mmol/L)                                  | 1.40<br>(1.19 – 1.80)      | 1.43<br>(1.20 – 1.79)      | 0.403  | 0.920  | 1.40<br>(1.19 – 1.70)      | 1.50<br>(1.20 – 1.80)      | 0.073 |
| LDL <sup>s</sup> (mmol/L)                                  | 3.40<br>(2.90 – 4.05)      | 3.12<br>(2.70 – 3.70)      | <0.001 | 0.038  | 3.23<br>(2.50 – 3.969)     | 3.01<br>(2.30 – 3.73)      | 0.100 |
| Glc <sup>t</sup> (mmol/L)                                  | 5.00<br>(4.50 – 5.60)      | 4.90<br>(4.40 – 5.30)      | 0.007  | <0.001 | 5.50<br>(4.90 – 6.00)      | 5.40<br>(5.00 – 5.89)      | 0.350 |
| Creatinine (mmol/L)  | 78.00<br>(69.00 – 88.75)   | 74.00<br>(65.00 – 82.25)   | <0.001 | 0.768  | 79.00<br>(68.00 – 89.00)   | 78.00<br>(70.00 – 84.25)   | 0.629 |
| RF <sup>u</sup> (IU/mL)                                    | 46.3<br>(10.0-155.0)       | 28.8<br>(8.0-139.5)        | 0,268  | ND     | ND                         | ND                         | ND    |
| <i>Smoking habit</i>                                       |                            |                            |        |        |                            |                            |       |
| Nonsmokers<br>n[% (95%CI)]                                 | 221<br>[59.2 (54.9, 64.9)] | 130<br>[51.2 (45.1, 57.3)] | 0.046  | <0.001 | 189<br>[73.3 (67.6, 78.3)] | 56<br>[59.69 (49.6, 69.0)] | 0.014 |
| Exsmokers, n[% (95%CI)]                                    | 89<br>[23.9 (19.9, 28.5)]  | 50<br>[19.7 (15.3, 25.0)]  | 0.217  | 0.010  | 40<br>[15.5 (11.6, 20.4)]  | 15<br>[16.0 (9.9, 24.7)]   | 0.917 |
| - duration yrs.  | 20.00<br>(13.50-30.00)     | 20.00<br>(10.00-25.00)     | 0.122  | 0.449  | 20.00<br>(10.00-30.00)     | 15.00<br>(7.00-20.00)      | 0.170 |
| Current smokers<br>n[% (95%CI)]                            | 63<br>[16.9 (13.4-21.0)]   | 74<br>[29.1 (23.9-35.0)]   | <0.001 | 0.048  | 29<br>[11.2 (7.9-15.6)]    | 23<br>[24.5 (16.9-34.0)]   | 0.002 |
| - duration yrs.  | 30.00<br>(20.00-40.00)     | 27.00<br>(20.00-34.00)     | 0.039  | 0.423  | 30.00<br>(22.00-33.50)     | 28.00<br>(20.00-37.00)     | 0.462 |
| - cigarettes/day   | 15 (10-20)                 | 10 (10-20)                 | <0.001 | 0.041  | 10 (4-20)                  | 20 (10-20)                 | 0.001 |
| <i>Medication</i>  |                            |                            |        |        |                            |                            |       |
| Antirheumatics<br>NSADs <sup>v</sup> users<br>n[% (95%CI)] | 180<br>[48.3 (43.3, 53.4)] | 133<br>[52.6 (46.5, 58.7)] | 0.328  | 0.002  | 163<br>[63.2 (57.2, 98.9)] | 69<br>[73.4 (63.7, 81.3)]  | 0.073 |
| MTX <sup>w</sup> users,<br>n[% (95%CI)]                    | 180<br>[48.3 (43.3, 53.4)] | 132<br>[52.0 (45.9, 58.1)] | 0.362  | ND     | 0                          | 0                          | ND    |
| Leflunomide users<br>,n[% (95%CI)]                         | 59<br>[15.8 (12.5, 19.8)]  | 26<br>[10.3 (7.1, 14.6)]   | 0.048  | ND     | 0                          | 0                          | ND    |
| Chloroquine users,<br>n[% (95%CI)]                         | 26<br>[10.2 (7.5, 13.7)]   | 33<br>[8.8 (5.9, 12.9)]    | 0.559  | ND     | 0                          | 0                          | ND    |
| Sulphosalazine users,<br>n[% (95%CI)]                      | 96<br>[25.7 (21.5, 30.4)]  | 61<br>[24.1 (19.3, 29.7)]  | 0.659  | Nd     | 0                          | 0                          | ND    |

|                                      |                            |                            |        |       |                            |                           |       |
|--------------------------------------|----------------------------|----------------------------|--------|-------|----------------------------|---------------------------|-------|
| Glucocorticoides                     |                            |                            |        |       |                            |                           |       |
| - users, n[% (95%CI)]                | 314<br>[84.2 (80.2, 87.6)] | 213<br>[83.9 (78.9, 87.9)] | 0.913  | ND    | 0                          | 0                         | ND    |
| - duration (month)                   | 4.0 (1.0-8.0)              | 2.0 (1.0-6.0)              | 0.008  | ND    | 0                          | 0                         | ND    |
| - dose (mg/day)                      | 20.0 (10.0-20.0)           | 20.0 (10.0-20.0)           | 0.632  | ND    | 0                          | 0                         | ND    |
| Anti-TNF <sup>y</sup> , n[% (95%CI)] | 16<br>[4.3 (2.7, 6.9)]     | 24<br>[9.5 (6.5, 13.7)]    | 0.009  | ND    | 0                          | 0                         | 0     |
| Analgesic users,<br>n[% (95%CI)]     | 134<br>[35.9 (31.2, 40.9)] | 71<br>[28.0 (22.8, 33.8)]  | 0.037  | 0.945 | 92<br>[35.7 (30.1, 41.7)]  | 29<br>[30.9 (22.5, 40.3)] | 0.401 |
| Opioids users,<br>n[% (95%CI)]       | 0                          | 1 [0.4]                    | ND     | ND    | 91<br>[35.3 (29.7, 41.3)]  | 30<br>[31.9 (23.3, 41.9)] | 0.557 |
| Antihypertensives                    |                            |                            |        |       |                            |                           |       |
| ACE-I <sup>x</sup> , n[% (95%CI)]    | 150<br>[40.2 (35.3, 45.8)] | 0                          | ND     | 0.002 | 137<br>[53.1 (49.0, 59.1)] | 0                         | ND    |
| BB <sup>z</sup> , n[% (95%CI)]       | 113<br>[30.3 (25.9, 35.1)] | 0                          | ND     | 0.930 | 79<br>[30.6 (25.3, 36.5)]  | 0                         | ND    |
| DIUR <sup>aa</sup> , n[% (95%CI)]    | 121<br>[32.4 (27.9, 37.3)] | 0                          | ND     | 0.004 | 113<br>[43.8 (37.9, 49.9)] | 0                         | ND    |
| ATRA <sup>ab</sup> , n[% (95%CI)]    | 13<br>[3.5 (2.1, 5.9)]     | 0                          | ND     | 0.173 | 15<br>[5.8 (3.5, 9.4)]     | 0                         | ND    |
| CCB <sup>ac</sup> , n[% (95%CI)]     | 94<br>[25.2 (21.1, 29.2)]  | 0                          | ND     | 0.001 | 96<br>[37.2 (31.5, 43.2)]  | 0                         | ND    |
| Anti-HT <sup>ad</sup> , drugs. no    | 2 (1-2)                    | 0                          | ND     | 0.008 | 2 (1-3)                    | 0                         | ND    |
| Anti-HT users,<br>n[% (95%CI)]       | 280<br>[75.1 (70.5, 79.2)] | 0                          | ND     | 0.002 | 222<br>[86.0 (81.2, 89.7)] | 0                         | ND    |
| Statins, n[% (95%CI)]                | 68<br>[18.2 (14.6, 22.0)]  | 17<br>[6.7 (4.2, 10.5)]    | <0.001 | 0.003 | 75<br>[29.1 (23.9, 34.9)]  | 10<br>[10.6 (5.9, 18.4)]  | 0.001 |

Results are expressed as percentages and 95%CI, median values (interquartile range) or mean values (standard deviation) as appropriate.

<sup>a</sup>RA, rheumatoid arthritis; <sup>b</sup>OA, osteoarthritis; <sup>c</sup>HT, hypertension; <sup>d</sup>NT, normotension; <sup>e</sup>CI, confidence interval; <sup>f</sup>BMI, body mass index; <sup>g</sup>ND, non-done; <sup>h</sup>W/H, waist/hip; <sup>i</sup>VASP, pain visual analog scale; <sup>j</sup>VASGH, General health visual analog scale; <sup>k</sup>HAQ, Health assessment questionnaire; <sup>l</sup>DAS28-CRP, Disease activity score, 28 joints and C-reactive protein; <sup>m</sup>DM, diabetes mellitus; <sup>n</sup>ESR, erythrocyte sedimentation rate; <sup>o</sup>CRP, C-reactive protein; <sup>p</sup>Chol, plasma cholesterol; <sup>q</sup>TG, plasma triglycerides; <sup>r</sup>HDL, high-density lipoprotein; <sup>s</sup>LDL, low-density lipoprotein; <sup>t</sup>Glc, plasma glucose; <sup>u</sup>RF, rheumatoid factor; <sup>v</sup>NSAIDs, non-steroidal anti-inflammatory drugs; <sup>w</sup>MTX, methotrexate; <sup>y</sup>TNF, tumor necrosis factor; <sup>x</sup>ACE-I, angiotensin-converting enzyme inhibitors; <sup>z</sup>BB,  $\beta$ -blockers; <sup>aa</sup>DIUR, diuretics; <sup>ab</sup>ATRA, angiotensin-II receptor antagonists; <sup>ac</sup>CCB, calcium channel blockers; <sup>ad</sup>Anti-HT, antihypertensives.

## Comments to table 1-S

### *Comparison of HT and NT (normotensive) RA and OA patients*

In both RA and OA patients, the HT subgroup was characterized by older patients and a higher proportion of the elderly, a longer duration of the disease (RA or OA), higher BMI and a greater proportion of overweight/obese patients, higher VASP, a higher proportion of dyslipidemic and DM patients and higher plasma LDL and triglyceride concentrations, compared with the NT patients. VASGH and HDL values were similar in HT and NT in both RA and OA patients.

The following variables had dissimilar differences between HT and NT patients in RA and OA: the proportion of female HT and NT patients was similar in the RA group, but higher in the HT patients of the OA group; WHR was higher in HT RA patients than in NT RA patients, but similar in HT and NT OA patients; ESR, CRP, Chol, LDL, and Glc concentrations were higher in HT than in NT patients in the RA group, but were similar in the HT and NT patients in the OA group. (Statistically significant difference for CRP in OA was so small that had no clinical significance).

Regarding variables measured only in the RA group, DAS28-CRP values and RF concentration were similar in the HT and NT patients, whereas HAQ was higher in the HT than in the NT patients.

Comparing HT and NT patients regarding smoking the HT group had a higher proportion of nonsmokers, a similar proportion of ex-smokers, and a lower proportion of current smokers than did the NT group for both RA and OA. The smoking duration of ex-smokers was similar in among the HT and NT patients with RA and with OA. For current smokers, the duration of smoking was similar and the number of cigarettes per day was higher in HT RA patients than in NT RA patients and lower in HT OA patients than in NT OA patients.

Regarding medications there were no statistically significant differences in the proportions of users of non-steroidal anti-inflammatory drugs (NSAIDs) between HT and NT patients in either the RA or OA group. The same was found for RA-specific medication, including various disease modifying anti-rheumatic drugs (DMARDs), glucocorticoids (GCs) and anti-tumor necrosis factor (anti-TNF) drugs. An exception to this finding was leflunomide, with a higher proportion of users in HT group and the use was associated with a higher prevalence of HT. than in nonusers (69.4 in users % vs. 58.1%, , P=0.048). Regarding GCs, only the duration of therapy was associated with HT; duration was longer in HT than in NT patients.

The proportions of antihypertensive users, in terms of their general use and in terms of specific drugs, were higher in OA HT patients than in the RA HT patients, except in the case  $\beta$ -

blockers and angiotensin-II receptor antagonists, which were used by similar proportions of patients in both groups.

Statins were used by a higher proportion of HT than NT patients in both the RA and OA groups, and the proportion of HT users was higher in OA than in RA patients.

*Comparison of hypertensive RA and OA patients*

The HT OA subgroup was characterized by higher age, a greater proportion of elderly patients, longer awareness of HT, higher BMI, a greater proportion of overweight/obese patients, a higher proportion of dyslipidemic and DM patients, and higher TG and Glc concentrations compared to HT RA patients. In contrast, the disease duration (RA or OA) was longer and ESR, CRP and LDL concentrations were higher in HT RA than in HT OA patients. The proportion of females, WHR, VASP, VASGH and Chol, HDL and creatinine concentrations were similar in HT RA and OA patients.

Table 2-S. Logistic regression analysis with HT<sup>a</sup> as dependent variable.

| Variable                             | OR (95%CI)           | P-value |
|--------------------------------------|----------------------|---------|
| <i>RA<sup>b</sup> group (n=627)</i>  |                      |         |
| Age                                  | 1.063 (1.038-1.090)  | <0.001  |
| RA_duration                          | 1.018 (0.985-1.053)  | 0.289   |
| BMI <sup>c</sup>                     | 1.108 (1.047-1.173)  | <0.001  |
| W/R <sup>d</sup> ratio               | 0.620 (0.042-9.193)  | 0.728   |
| VASP <sup>e</sup>                    | 1.006 (0.995-1.017)  | 0.304   |
| HAQ <sup>f</sup>                     | 0.972 (0.718-1.315)  | 0.853   |
| Dyslipidemia                         | 1.316 (0.805-2.1529) | 0.273   |
| DM <sup>g</sup>                      | 1.348 (0.445-4.090)  | 0.597   |
| ESR <sup>h</sup>                     | 1.008 (0.995-1.022)  | 0.217   |
| Chol <sup>i</sup>                    | 1.002 (0.921-1.089)  | 0.971   |
| LDL <sup>j</sup>                     | 1.047 (0.806-1.360)  | 0.732   |
| TG <sup>k</sup>                      | 1.206 (0.920-1.581)  | 0.174   |
| Creatinine                           | 1.014 (1.000-1.028)  | 0.042   |
| Glc <sup>l</sup>                     | 1.113 (0.874-1.418)  | 0.386   |
| Cigarette per day                    | 0.977 (0.943-1.013)  | 0.212   |
| Glucocorticoid . duration of therapy | 1.036 (0.976-1.099)  | 0.246   |
| <i>OA<sup>m</sup> group (n=352)</i>  |                      |         |
| Age                                  | 1.052 (1.020-1.085)  | 0.001   |
| OA duration                          | 1.036 (0.994-1.079)  | 0.095   |
| BMI <sup>c</sup>                     | 1.126 (1.051-1.207)  | 0.001   |
| VASP <sup>d</sup>                    | 1.023 (1.009-1.037)  | 0.001   |
| Dyslipidemia                         | 1.818 (1.011-3.270)  | 0.046   |
| DM <sup>e</sup>                      | 1.606 (0.637-4.046)  | 0.315   |
| TG <sup>f</sup>                      | 1.223 (0.875-1.710)  | 0.239   |
| Cigarettes per day                   | 0.950 (0.890-1.014)  | 0.126   |

Variables significantly different between HT and NT subgroups (table 1-S) were introduced in the model.

HT<sup>a</sup>, hypertension; RA<sup>b</sup>, rheumatoid arthritis; BMI<sup>c</sup>, body mass index; W/R<sup>d</sup>, waist/hip; VASP<sup>e</sup>, pain visual analog scale; HAQ<sup>f</sup>, Health assessment questionnaire; DM<sup>g</sup>, diabetes mellitus; ESR<sup>h</sup>, erythrocyte sedimentation rate; Chol<sup>i</sup>, plasma cholesterol; LDL<sup>j</sup>, low-density lipoprotein, TG<sup>k</sup>, plasma triglycerides; Glc<sup>l</sup>, plasma glucose, <sup>m</sup>OA, osteoarthritis,.